Mainz Biomed (NASDAQ:MYNZ) Short Interest Up 61.2% in March

Mainz Biomed (NASDAQ:MYNZ) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 128,500 shares, an increase of 61.2% from the February 28th total of 79,700 shares. Based on an average daily volume of 214,900 shares, the days-to-cover ratio is presently 0.6 days. Currently, 6.1% of the shares of the company are sold short.

Mainz Biomed Price Performance

Shares of Mainz Biomed stock traded down $0.39 during trading on Friday, hitting $3.58. 263,338 shares of the company’s stock traded hands, compared to its average volume of 96,360. The company has a market cap of $7.16 million, a PE ratio of -0.05 and a beta of 0.33. The firm’s fifty day moving average price is $5.40 and its 200 day moving average price is $7.40. Mainz Biomed has a twelve month low of $3.29 and a twelve month high of $45.20.

Institutional Investors Weigh In On Mainz Biomed

An institutional investor recently bought a new position in Mainz Biomed stock. Virtu Financial LLC bought a new position in shares of Mainz Biomed (NASDAQ:MYNZ) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 18,330 shares of the company’s stock, valued at approximately $79,000. Virtu Financial LLC owned 0.92% of Mainz Biomed at the end of the most recent reporting period.

Analyst Ratings Changes

Separately, Maxim Group assumed coverage on Mainz Biomed in a research report on Friday, February 14th. They set a “buy” rating and a $14.00 price objective on the stock.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.